Navigation Links
Advanced Life Sciences to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference
Date:2/26/2008

CHICAGO, Feb. 26 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that it will present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference held March 4th-5th in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

Advanced Life Sciences' President, John Flavin will make a corporate presentation to investors on Wednesday, March 5 at 12:30 PM ET. The Company's presentation will be delivered in the Sea/Ocean Room at The W Hotel, 541 Lexington Avenue in New York City. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, http://www.advancedlifesciences.com. Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.

About Advanced Life Sciences

Advanced Life Sciences' is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections such as community acquired pneumonia (CAP). In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post-exposure, but the drug is not yet approved for this or any other indication. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer
2. FDA OKs Avastin for Advanced Breast Cancer
3. Perot Systems and Oakwood Healthcare Deliver Advanced Technology & Revenue Cycle Solutions to Physicians
4. American Imaging Management Launches Patient Safety Program to Increase Awareness of Radiation Dose Associated with Advanced Imaging Procedures
5. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
6. Major study links insurance status to advanced stage in multiple cancers
7. Early warning: PSA testing can predict advanced prostate cancer
8. PSA testing can predict advanced prostate cancer
9. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
10. New Jefferson trial to test radiation-emitting beads against advanced liver cancer
11. LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, ... in Europe for public health and the environment and is calling on the United ... and the overwhelming support of European citizens, the European Union (EU) will, beginning next ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex ... of “Profiling protein expression in circulating tumor cells using microfluidic western blotting” in ... of the Vortex technology to capture CTCs and a microfluidic single-CTC ...
(Date:3/22/2017)... ... 22, 2017 , ... Sam & Associates Insurance Agency, a ... related services to residents of the region, is embarking on a charity effort ... wild lands. , Endangered Species International is committed to ending the anthropogenic trends ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... consuming and frustrating and this tool bypasses that. Healthcare facilities across the ... an opportunity to offer their clients and hospitals, across the country, an efficient ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... ... cannabis market was worth an estimated $6.6 billion in 2016, and ... of 16% or reaching more than $24 billion by 2025. The ... 2025, or growing from $4.7 billion in 2016, to an estimated ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
Breaking Medicine Technology: